Company profile
CardiaTec Biosciences
CardiaTec is a digital biotechnology venture combining the power of AI and expert talent to redesign cardiovascular drug discovery to deliver the next generation of therapeutics
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
SH01 | Transaction MzQzODk0NTA3OWFkaXF6a2N4
Published 09 Oct 2024 03:58
SH01 | Transaction MzQzNjM3OTI3NWFkaXF6a2N4
Published 18 Sep 2024 11:50
SH01 | Transaction MzQzNjM3ODY3NmFkaXF6a2N4
Published 18 Sep 2024 11:45
SH01 | Transaction MzQzNjM3ODAwMWFkaXF6a2N4
Published 18 Sep 2024 11:40
SH01 | Transaction MzQzNjM3NzY2MWFkaXF6a2N4
Published 18 Sep 2024 11:37
Company registered at Companies House
1 Oct 2025 to 30 Sep 2027
Hypertrophic cardiomyopathy (HCM) is a hereditary heart condition that affects approximately 1 in 500 individuals in the UK and Germany. Often leading to significant health challenges and an increased risk of sudden cardiac events, despite its prevalence, current treatment options are limited, and there is an urgent need to support the development of inno...
